Last updated: 2026-09-16 11:41:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Profound Medical Corp. (PROF) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $5.70, with a market capitalisation of $212.30M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.90 to $8.95. This page covers its latest market performance, valuation, price trends and company information.
$212.30M | |
$5.82 | |
$28.97 | |
$3.10 | |
$5.81 | |
102.44K | |
107.91K | |
-- | |
$8.95 | |
$3.90 | |
-- | |
-- |
Profound Medical Corp. (PROF) is trading at $5.97 in pre-market trading as of 2026-09-15 23:31:00, up 2.69% ($0.16) from the previous close of $5.81
Pre-market trading shows how investors are pricing PROF before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Profound Medical Corp. (PROF) moved from $6.89 to $5.70, representing a decline of 17.26% ($1.19).
The stock traded between $5.50 and $6.96 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 168.20 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 35.7%
PROF is currently trading at $5.70, placing it 35.7% of the way from its 52-week low of $3.90 to its 52-week high of $8.95. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 162 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Profound Medical Corp. (PROF) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.